Nothing Special   »   [go: up one dir, main page]

DE69333057D1 - Rekombinente Adenoviren-Impfstoffe - Google Patents

Rekombinente Adenoviren-Impfstoffe

Info

Publication number
DE69333057D1
DE69333057D1 DE69333057T DE69333057T DE69333057D1 DE 69333057 D1 DE69333057 D1 DE 69333057D1 DE 69333057 T DE69333057 T DE 69333057T DE 69333057 T DE69333057 T DE 69333057T DE 69333057 D1 DE69333057 D1 DE 69333057D1
Authority
DE
Germany
Prior art keywords
recombinant adenoviruses
antibodies
recombinant adenovirus
cell mediated
mediated immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69333057T
Other languages
English (en)
Other versions
DE69333057T2 (de
Inventor
Alan Robert Davis
Paul Porwen Hunt
Micheal David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE69333057D1 publication Critical patent/DE69333057D1/de
Application granted granted Critical
Publication of DE69333057T2 publication Critical patent/DE69333057T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69333057T 1992-08-07 1993-07-23 Rekombinente Adenoviren-Impfstoffe Expired - Fee Related DE69333057T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92649192A 1992-08-07 1992-08-07
US926491 1992-08-07

Publications (2)

Publication Number Publication Date
DE69333057D1 true DE69333057D1 (de) 2003-07-31
DE69333057T2 DE69333057T2 (de) 2004-07-08

Family

ID=25453282

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333057T Expired - Fee Related DE69333057T2 (de) 1992-08-07 1993-07-23 Rekombinente Adenoviren-Impfstoffe

Country Status (17)

Country Link
EP (1) EP0586076B1 (de)
JP (1) JP4093597B2 (de)
KR (1) KR100347219B1 (de)
AT (1) ATE243755T1 (de)
AU (2) AU680826B2 (de)
BR (1) BR9303226A (de)
CA (1) CA2101463C (de)
DE (1) DE69333057T2 (de)
DK (1) DK0586076T3 (de)
ES (1) ES2201055T3 (de)
FI (1) FI114318B (de)
HU (2) HU214364B (de)
IL (1) IL106508A (de)
MX (1) MX9304765A (de)
NZ (1) NZ248328A (de)
PT (1) PT586076E (de)
ZA (1) ZA935355B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0638316T3 (da) * 1993-08-11 2003-09-22 Wyeth Corp Rekombinante adenovirusvacciner
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
AU4743196A (en) * 1994-12-30 1996-07-24 Chiron Corporation Non-traumatic administration of gene delivery vehicles
KR100464395B1 (ko) * 1997-10-13 2005-02-28 삼성전자주식회사 반도체소자의비아홀형성방법
EP1200622A4 (de) 1999-07-06 2004-12-22 Merck & Co Inc Hiv impfstoff aus einem das gag-gen tragenden adenovirus
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
CN101917944B (zh) 2007-08-21 2014-11-19 斯尔替克美学股份有限公司 监视诸如脂肪组织的冷却这种皮下富含脂质的细胞的冷却
KR20120113788A (ko) 2010-01-25 2012-10-15 젤티크 애스세틱스, 인코포레이티드. 상 변화 냉각제를 경유하여 피하 지질-풍부 세포로부터 열을 비침습성으로 제거하기 위한 가정용 어플리케이터 및 연관 디바이스, 시스템 및 방법
WO2012103242A1 (en) 2011-01-25 2012-08-02 Zeltiq Aesthetics, Inc. Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells
JP2021532873A (ja) 2018-07-31 2021-12-02 ゼルティック エステティックス インコーポレイテッド 皮膚特性を改善する方法、デバイス、及びシステム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
EP0563323A4 (en) * 1990-12-19 1996-02-28 Epitope Inc Hiv reverse transcriptase vaccine
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes

Also Published As

Publication number Publication date
IL106508A (en) 1998-02-22
HUT67302A (en) 1995-03-28
JP4093597B2 (ja) 2008-06-04
AU680826B2 (en) 1997-08-14
CA2101463C (en) 2007-03-13
MX9304765A (es) 1995-01-31
PT586076E (pt) 2003-11-28
BR9303226A (pt) 1994-03-08
HU211691A9 (en) 1995-12-28
AU715190B2 (en) 2000-01-20
CA2101463A1 (en) 1994-02-08
EP0586076A3 (de) 1994-04-20
JPH06165689A (ja) 1994-06-14
FI933495A0 (fi) 1993-08-06
KR100347219B1 (ko) 2003-02-25
AU3422797A (en) 1997-11-20
EP0586076B1 (de) 2003-06-25
ES2201055T3 (es) 2004-03-16
AU4446593A (en) 1994-02-10
ATE243755T1 (de) 2003-07-15
IL106508A0 (en) 1993-11-15
KR940003566A (ko) 1994-03-12
FI933495L (fi) 1994-02-08
HU9302285D0 (en) 1993-11-29
DE69333057T2 (de) 2004-07-08
HU214364B (hu) 1998-03-30
HK1009978A1 (en) 1999-06-11
ZA935355B (en) 1995-01-23
EP0586076A2 (de) 1994-03-09
NZ248328A (en) 1997-05-26
DK0586076T3 (da) 2003-10-20
FI114318B (fi) 2004-09-30

Similar Documents

Publication Publication Date Title
DE69333057D1 (de) Rekombinente Adenoviren-Impfstoffe
AU576907B2 (en) Oral vaccines comprising live recombinant adenoviruses
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
ATE241385T1 (de) Rekombinante adenovirus-vakzinen
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DK498387D0 (da) Virus-dna-sekvens
MX9201970A (es) Proteinas superficiales del virus de la hepatitis b con un contenido reducido del carbohidrato huesped.
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee